We are live on ! Find out more
ADMA icon

ADMA Biologics
ADMA

105 hedge funds and large institutions have $85.4M invested in ADMA Biologics in 2021 Q1 according to their latest regulatory filings, with 27 funds opening new positions, 35 increasing their positions, 25 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

69% more first-time investments, than exits

New positions opened: 27 | Existing positions closed: 16

40% more repeat investments, than reductions

Existing positions increased: 35 | Existing positions reduced: 25

12% more funds holding

Funds holding: 94 → 105 (+11)

4% less capital invested

Capital invested by funds: $88.7M → $85.4M (-$3.32M)

7.68% less ownership

Funds ownership: 47.71% → 40.03% (-7.7%)

60% less call options, than puts

Call options by funds: $1.53M | Put options by funds: $3.79M

Holders
105
Holders Change
+11
Holders Change %
+11.7%
% of All Funds
1.84%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
27
Increased
35
Reduced
25
Closed
16
Calls
$1.53M
Puts
$3.79M
Net Calls
-$2.26M
Net Calls Change
-$1.44M

Top Buyers

1
N
Nuveen
North Carolina
+$14.9M
2
MS
Maven Securities
Jersey
+$1.72M
3
BCM
Bridgeway Capital Management
Texas
+$1.24M
4
Bank of America
Bank of America
North Carolina
+$1.11M
5
Squarepoint
Squarepoint
New York
+$1.04M

Top Sellers

1
Marshall Wace
Marshall Wace
United Kingdom
-$4.86M
2
6CM
683 Capital Management
New York
-$3.9M
3
CCM
Consonance Capital Management
New York
-$3.04M
4
Franklin Resources
Franklin Resources
California
-$1.36M
5
EIM
Essex Investment Management
Massachusetts
-$1.22M
Name Holding Trade Value Shares
Change 		Change in
Stake
Marshall Wace
101
Marshall Wace
United Kingdom
– -$4.86M -2,490,900 Closed
6CM
102
683 Capital Management
New York
– -$3.9M -2,000,000 Closed
CCM
103
Consonance Capital Management
New York
– -$3.04M -1,558,290 Closed
EIM
104
Essex Investment Management
Massachusetts
– -$1.22M -627,931 Closed
TI
105
Telemetry Investments
New York
– -$391K -200,615 Closed
Russell Investments Group
106
Russell Investments Group
United Kingdom
– -$241K -123,968 Closed
HSA
107
Hussman Strategic Advisors
Maryland
– -$160K -82,000 Closed
Millennium Management
108
Millennium Management
New York
– -$102K -52,264 Closed
Manulife (Manufacturers Life Insurance)
109
Manulife (Manufacturers Life Insurance)
Ontario, Canada
– -$865K -33,218 Closed
E
110
Ergoteles
New York
– -$59K -30,100 Closed
DMK
111
David M. Knott
– -$42K -21,457 Closed
Ameriprise
112
Ameriprise
Minnesota
– -$44K -21,400 Closed
WC
113
Wexford Capital
Florida
– -$36K -18,605 Closed
IAA
114
Independent Advisor Alliance
North Carolina
– -$20K -10,193 Closed
ED
115
Exane Derivatives
France
– -$2.96K -1,517 Closed
ASN
116
Advisory Services Network
Georgia
– -$3K -1,500 Closed
AIC
117
Archer Investment Corporation
Indiana
– +$915 +400 New
1 2 3 4
5

ADMA Hedge Fund Activity: Q1 2021 in Review

105 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in ADMA Biologics (ADMA) for Q1 2021, worth a combined $85.4M — down 3.7% from $88.7M a quarter earlier.

Buyers outnumbered sellers: 27 funds opened new ADMA positions and 16 closed out — a net gain of 11 holders — while 35 added to existing stakes and 25 trimmed.

The largest buyer was Nuveen, adding an estimated $14.9M. The largest seller was Marshall Wace, exiting entirely with an estimated $4.86M sold.

  • 105 institutional investors held ADMA Biologics (ADMA) as of Q1 2021, up from 94 in Q4 2020.
  • Funds reported $85.4M of ADMA Biologics stock for Q1 2021, down 3.7% quarter-over-quarter.
  • 27 funds opened new ADMA Biologics positions in Q1 2021 and 16 closed out, a net change of +11 holders.
  • The largest ADMA Biologics buyer in Q1 2021 was Nuveen, an estimated $14.9M added.
  • The largest ADMA Biologics seller in Q1 2021 was Marshall Wace, an estimated $4.86M sold.

Based on aggregated 13F filings for Q1 2021.